Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials

Preetha Balasubramanian<sup>1,2</sup>, Constance Williams<sup>3</sup>, Mariya B. Shapiro<sup>4,5</sup>, Faruk Sinangil<sup>6</sup>, Keith Higgins<sup>6</sup>, Arthur Nádas<sup>7</sup>, Maxim Totrov<sup>8</sup>, Xiang-Peng Kong<sup>9</sup>, Andrew J. Fiore-Gartland<sup>10</sup>, Nancy L. Haigwood<sup>4,5</sup>, Susan Zolla-Pazner<sup>2</sup>, Catarina E Hioe<sup>2,11\*</sup>

Word count: Abstract 199, Main Text 4057

\*Corresponding author: Catarina E. Hioe, Department of Medicine – Division of Infectious Diseases, One Gustave L. Levy Place, Box 1090, New York, NY 10029 (catarina.hioe@mssm.edu).

<sup>&</sup>lt;sup>1</sup>The Sackler Institute of Graduate Biomedical Sciences, NYU School of Medicine, New York, NY 10016, USA

<sup>&</sup>lt;sup>2</sup>Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

<sup>&</sup>lt;sup>3</sup>Department of Pathology, NYU School of Medicine, New York, NY 10016, USA

<sup>&</sup>lt;sup>4</sup>Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA

<sup>&</sup>lt;sup>5</sup>Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA

<sup>&</sup>lt;sup>6</sup>Global Solutions for Infectious Diseases, South San Francisco, CA 94080, USA


<sup>&</sup>lt;sup>7</sup>Department of Environment Medicine, NYU School of Medicine, New York, NY 10016, USA

<sup>&</sup>lt;sup>8</sup>Molsoft LLC, La Jolla CA 92037, USA

<sup>&</sup>lt;sup>9</sup>Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016, USA

<sup>&</sup>lt;sup>10</sup>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA

<sup>&</sup>lt;sup>11</sup>James J. Peters VA Medical Center, Bronx, NY 10468, USA



**Supplemental Figure S1.** Correlation between ELISA  $OD_{405}$  and AUC values for 6 VAX003 and 3 VAX004 vaccinees at early, mid-, and final time points against cyclic V3 MN.  $OD_{405}$  were determined with plasma samples diluted 1:100. AUCs were calculated from titration curves starting with 1:100, 3-fold down, for 8 dilutions. Correlation analysis was performed using the nonparametric Spearman test.